Systematic Exposition of Mesenchymal Stem Cell for Inflammatory Bowel Disease and Its Associated Colorectal Cancer

Table 3

CLINICAL data of representative MSCs therapy for IBD from Pubmed in the past decade.

	Sources	Disease	Therapeutic schedule	Phase	Number	Evaluation	Outcome	Reference
1	Allogeneic-; BMMSCs	UC	a single dose of; (1.5-2) x 10^8 intravenously	II	44	24 months	34 (72.7%) of patients achieved the clinical; and morphological indices of inflammatory activity↓.	[112]
2	Allogeneic-; ADMSCs	Perianal fistulizing CD	a single dose of; 1.2 x 10^8 intralesionally	III	212	24 weeks	50% of patients treated with ADMSCs achieved combined remission.	[113]
3	Allogeneic-; ADMSCs	Perianal fistulizing CD	a single dose intralesionally; If 2 x 10^7 failed, 4 x 10^7 subsequently	II	24	24 weeks	69.2% of patients achieved the number of draining fistulas↓; 56.3% of patients achieved complete fistula closure of the treated.; 30% of patients achieved complete closure of all existing fistula tracts.	[114]
4	Allogeneic-; BMMSCs	Perianal fistulizing CD	a single dose of 1 × 10^7,; 3 × 10^7, or 9 × 10^7 intralesionally	II	21	6, 12, and 24 weeks	no severe adverse events.; 3 × 10^7 MSCs appeared to promote healing of perianal fistulas	[115]
5	Allogeneic-MSCs	Luminal CD	a single dose of; 2 × 10^6 /kg weekly for; 4 weeks intravenously	II	16	42 days	15 patients CDAI score ↓ from 370 to 203 at day 42	[116]
6	Autologous-BMMSCs	Luminal CD	two doses of; 1-2×10^6 intravenously,; 7 days apart	I	10	0, 6 weeks	3 patients CDAI score ↓ at 6 weeks	[117]
7	Autologous-ADMSCs	Perianal fistulizing CD	local injection,2×10^7	I	12	24 weeks	9 of 12 patients had complete clinical healing by 3 months,; 10 of 12 patients (83.3%) had complete clinical healing at 6 months	[118]
8	Autologous-ADMSCs	Perianal fistulizing CD	group 1: 1 × 10^7 cells/ml. After 4 weeks, if safe,; group 2: 2 × 10^7 cells/ml. After 4 weeks, if safe,; group 3: 4 × 10^7 cells/ml	I	>9	8 weeks	2 patients in group 2 showed complete healing; and 3 patients in group 3 showed complete healing at week 8.	[119]
9	Autologous-BMMSCs	CD	a single dose of; 2 × 10^7, 5 × 10^7,; or 10 × 10^7 cells/kg intravenously	I	12	2 weeks	Single infusion of BMMSCs propagated ex vivo; using human platelet lysate-supplemented media; was safe and feasible at the doses of up to 10 million cells/kg	[120]
10	Autologous-ADMSCs	Perianal fistulizing CD	3 × 10^7 cells per centimeter length	II	43	8 weeks	27/33 patients (82%) had complete fistula healing.; Of 27 patients, 23 patients (88%) sustained complete closure	[121]